Document:

Form of Product Supply Agreement

 Exhibit 10.25.0 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED ON 

A REQUEST FOR CONFIDENTIAL TREATMENT 

OMITTED PORTIONS HAVE BEEN SEPARATELY FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION 

Form of Long Term Supply Agreement 

FORM OF PRODUCT SUPPLY AGREEMENT 

Product Supply Agreement (this “Agreement”) dated as of
[            ], 2010, between, SEADRIFT COKE L.P., a limited partnership organized under the laws of the State of Texas with offices at 8618 State Highway 185 North, Port
Lavaca, Texas 77979 (“Seller”), and C/G ELECTRODES, LLC, a Delaware limited liability corporation with offices at 800 Theresia Street, Saint Marys, Pennsylvania 15857 (“Buyer” and, together with Seller,
individually, a “Party” and collectively, the “Parties”), for the sale and purchase of calcined petroleum needle coke (“Coke”) produced at Seller’s facility in Port Lavaca, Texas. 

NOW THEREFORE, in consideration of the mutual covenants and promises herein contained and other good and valuable consideration, the
receipt and legal sufficiency of which is hereby acknowledged, Seller and Buyer agree as follows: 
 1.0 Effective Date; Term 

 1.1 The initial term of this Agreement shall commence on the date hereof and continue through December 31, 2017 (the
“Initial Term”); provided, however, that, the Initial Term shall be extended for Renewal Terms in accordance with Section 1.2. 

1.2 The term of this Agreement shall automatically renew for consecutive three (3) year terms after the Initial Term (each, a
“Renewal Term” and, together with the Initial Term, the “Term”); provided that this Agreement may be terminated at the end of the Initial Term or any Renewal Term only upon delivery by either Seller or Buyer of
written notice of non-renewal to the other Party at least three (3) years in advance of the expiration of the Initial Term or a Renewal Term. By way of example, (i) in order for the Agreement not to be renewed at the end of the
Initial Term, written notice must be given not later than December 31, 2014, and (ii) in order for the Agreement not to be renewed at the end of any subsequent Renewal Term, written notice must be given not later than three
(3) years prior to the last date of the then applicable Renewal Term. 
 1.3 For the purposes hereof, each period of
January 1 through December 31 during the Term shall be referred to as a “Calendar Year.” The period from the Effective Date through December 31, 2010 shall be referred to as the “Initial Period.”

 1.4 Notwithstanding anything in this Article 1.0, this Agreement may be earlier terminated by either Seller or Buyer pursuant
to Article 10.0 hereof. 
  

 1 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 2.0 Quality 

2.1 Subject to the other provisions of this Agreement, Seller shall manufacture electrode grade of Coke. Coke sold pursuant to this
Agreement will have physical properties that conform to those specifications listed in the applicable Exhibit A (the “Product Specifications”), attached hereto and incorporated herein. 

2.2 The quality of Coke delivered hereunder will be tested by utilizing testing samples (the “Test Samples”), as
described in Section 2.3 below, which will be taken by Seller prior to the Coke being loaded at Seller’s facility in Port Lavaca, Texas, or at such other loading facility as may be mutually agreed upon by Buyer and Seller. 

2.3 Seller will divide each Test Sample into two (2) approximately equal portions. Seller will (i) test one portion at its own
laboratory to determine the Coke’s compliance with the Product Specifications, and (ii) if requested by Buyer, expeditiously forward the other portion to Buyer. The frequency of extracting the Test Samples for testing will be determined by
Seller in its reasonable discretion based upon traceable production lots. 
 2.4 Upon receipt of the Test Sample results from
its laboratory, Seller will prepare a Quality Certificate which it will promptly send to Buyer. Buyer will have five (5) business days from receipt of the Quality Certificate to object to the findings of the Quality Certificate. If no objection
is received by Seller within this time, and if Seller’s own test results show that the Coke complies with the Product Specifications, then Seller may, at its option, ship the Coke to Buyer without further approval from Buyer. If Buyer timely
objects to Seller’s Quality Certificate, then Seller shall, pursuant to the provisions of Section 2.3(ii), send the second portion of the Test Sample to Buyer. Upon receipt of such Test Sample, Buyer may, at its own cost, test the Test
Sample to determine compliance with the Product Specifications and notify Seller of the results within a reasonable period not to exceed thirty (30) days from the date of receipt of the Test Sample. 

2.5 Notwithstanding any provision to the contrary set forth in this Agreement, Buyer’s receipt of the Coke delivered hereunder at
Buyer’s destination shall be an unqualified acceptance of and waiver by Buyer of any and all claims that Buyer may have against Seller with respect to the quality of the delivered Coke, unless Seller receives written notice of Buyer’s
notification to the contrary within sixty (60) days following Buyer’s receipt of shipment. 
 3.0 Quantity 

3.1 Seller shall be required to manufacture, ship, deliver and sell to Buyer the quantity of Coke ordered by Buyer up to but not in excess
of the Seller Minimum Quantity (as defined below) of Coke. For the purposes hereof, the term “Seller Minimum Quantity” shall mean, as to each relevant period, (i) pro rata portion of * metric tons during the Initial

  

 2 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 
Period, (ii) * metric tons during 2011, and (iii) for each Calendar Year after 2011, an amount equal to the Seller Minimum Quantity during the prior Calendar Year plus * metric tons.

 3.2 Buyer shall be obligated to purchase and accept for delivery not less than the Buyer Minimum Quantity (as defined below)
of Coke. For the purposes hereof, the term “Buyer Minimum Quantity” shall mean, as to each relevant period, the lesser of (i) the Seller Minimum Quantity, as above defined, or (ii) * percent (*%) of Buyer’s aggregate
purchases of Coke from any and all sources during such period.  
 3.3 In order to give effect to Buyer’s obligation
to purchase, and Seller’s obligation to sell, the Seller Minimum Quantity and Buyer Minimum Quantity, respectively, and to assure that such purchases and sales are made throughout each Year: 

a. On or before forty (45) days prior to the beginning of each Calendar Year, Buyer shall provide Seller with an estimate of its
purchases during such Calendar Year broken down by quarter. 
 b. On or before forty (45) days prior to the beginning of
each of the second, third and fourth calendar quarters of each Calendar Year, Buyer shall provide Seller with an updated estimate of its purchases for the remainder of such Calendar Year broken down by quarter. 

c. The estimated purchases, per the above, for the first calendar quarter during each of the above periods (the “Quarterly
Estimate”) may not, without Seller’s consent, exceed * (*%) percent of the Seller Minimum Quantity. 
 3.4 If
Buyer wishes to purchase more than the Seller Minimum Quantity, Buyer shall include such proposed additional quantity (the “Additional Quantity”) as part of the discussion with respect to the applicable delivery schedule, as
provided in Article 6.0 below. For the avoidance of doubt, however, unless the Parties shall have agreed to an Additional Quantity in writing Seller shall not be obligated to purchase more than the Seller Minimum Quantity. 

3.5 The quantity of Coke delivered shall be determined by railroad weigh scales at Seller’s facility for shipments by railcars.
Unless otherwise agreed by the Parties, Seller shall bear the cost of weighing the Coke delivered into Buyer’s railcars. 

3.6 The Coke sold hereunder shall be used by Buyer solely to make graphite electrodes at the St. Mary’s plant, and not for
redistribution to other persons or entities or for the manufacture of other products or manufacture of graphite electrodes at other facilities; provided that up to * percent (*%) of the Buyer Minimum Quantity of Coke may be used by Buyer for other
purposes during each Calendar Year. 
 3.7 In the event that Buyer fails to order for delivery and purchase at least (i) *
(*%) percent of the Quarterly Estimate (the “Quarterly Requirement”) during the applicable calendar quarter or (ii) the Buyer Minimum Quantity during a Calendar Year, Buyer shall, without duplication, pay to Seller the Buyer
Shortfall Payment. 
  

 3 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 For the purposes hereof, (i) the “Buyer Shortfall Amount,”
(1) applicable to a quarter shall be the (x) number of metric tons constituting the Quarterly Requirement reduced by (y) the actual metric tons ordered by Buyer for delivery during such period and (2) the Buyer Shortfall
Amount applicable to a Calendar Year shall be (x) the number of metric tons constituting the Buyer Minimum Quantity reduced by (y) the actual metric tons ordered by Buyer for delivery during such period, and (ii) the
“Buyer Shortfall Payment” shall be (x) *% of the Buyer Shortfall Amount multiplied by (y) the price for the Coke during the applicable period. 

Any Buyer Shortfall Payment shall be due not later than ten (10) days following the end of the applicable period. 

3.8 Provided that Buyer has ordered such quantities for delivery during such period, in the event that Seller fails to deliver at least
(i) the Quarterly Requirement during the applicable calendar quarter or (ii) the Buyer Minimum Quantity during a Calendar Year, Seller shall pay to Buyer, without duplication, the Seller Shortfall Payment. 

For the purposes hereof, (i) the “Seller Shortfall Amount,” (1) applicable to a quarter shall be (x) the
number of metric tons constituting the Quarterly Requirement, reduced by (y) the actual metric tons delivered by Seller to Buyer during such period and (2) the Seller Shortfall Amount applicable to a Calendar Year shall be
(x) the number of metric tons which have been included in the Quarterly Estimates during such Calendar Year and which have been ordered by Buyer for delivery during such Calendar Year up to the Seller Minimum Quantity reduced by
(y) the actual metric tons delivered by Seller to Buyer during such period, and (ii) the “Seller Shortfall Payment” shall be (x) *% of the Seller Shortfall Amount multiplied by (y) the price for the
Coke during the applicable period. 
 Any Seller Shortfall Payment shall be due not later than ten (10) days following the
end of the applicable Period. 
 4.0 Purchase Price 

4.1 The price for the Initial Period shall be $* per metric ton. 

4.2 Seller shall communicate to Buyer the price for a subsequent Calendar Year within ninety (90) days prior to the expiration of
the then current year. 
 4.3 Seller and Buyer shall agree upon a mutually acceptable price for each Calendar Year within thirty
(30) days after the proposed price is communicated. 
 4.4 Notwithstanding Section 4.3, but subject to the provisions
of Section 4.5, Seller may increase the price hereunder from time to time at its reasonable discretion to 
  

 4 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 
reflect changes in the cost of its raw materials by giving written notice to Buyer of at least thirty (30) days prior to the effective date of any such increase. Each increase in price shall
apply to all shipments of Coke hereunder on or after the effective date of such increase. 
 4.5 Notwithstanding Sections 4.3
and 4.4, in no event will the price for Coke at any time exceed *. For the purposes of this Agreement, the term “*” shall mean *. In order to give effect to the foregoing, Buyer may furnish written evidence to Seller that * and Seller
shall be obligated to *. If *, or if Seller and Buyer otherwise agree to *, the * shall be * as mutually agreed by Buyer and Seller. 

4.6 Except where law otherwise provides, Buyer shall pay Seller, in addition to the price, the amount of all governmental taxes, excise
duties and other charges (except taxes on Seller’s net income) that Seller may be required to pay with respect to (a) the sale of Coke delivered hereunder and (b) the manufacture or transportation of the Coke delivered hereunder.

 5.0 Invoicing and Payment 

5.1 For all shipments of Coke hereunder, Seller’s corresponding invoices shall be due and payable in available U.S. dollars within *
(*) days following the date of departure from Seller’s facility. 
 5.2 Buyer shall include with its payment, the
invoice number and a statement that payment is for the purchase of Coke. If the payment due date falls on a day when Seller’s bank is closed, payment shall be due on the succeeding banking day. 

5.3 If payment from Buyer is past due by more than thirty (30) days, Buyer agrees to pay interest on such past due invoices at the
lower of the interest rate of 1.5% per month (18% per annum) or the maximum interest rate permitted by applicable law. If payment from Buyer is past due by more than ninety (90) days, Seller may, in its sole discretion, suspend further
performance under this Agreement until such past due amount is paid in full. Buyer agrees to reimburse Seller for all costs that Seller may reasonably incur (including attorneys’ fees) in collecting Buyer’s past due amounts. 

6.0 Delivery; Transfer of Title 

6.1 The Parties shall mutually agree upon a delivery schedule for the Coke ordered hereunder. The quantities of Coke to be delivered and
the dates of delivery shall be in accordance with the then current delivery schedule. 
 6.2 Buyer shall place a written order
with Seller for all Additional Quantities of Coke within a reasonable time in advance of the desired date of delivery (which period shall not be less than ninety (90) days from the desired date of delivery). 

6.3 Packaged shipments, if any, shall be made in Seller’s standard containers. 

 

 5 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 6.4 All shipments shall be FOB Seadrift into railcars (or other mode of delivery agreed
by the Parties) at Seller’s Port Lavaca, Texas facility. Title, all risks of loss and all responsibilities for insurance and costs of shipment shall pass at Seller’s Port Lavaca, Texas facility. 

7.0 Warranties. 

Seller warrants that it has title to Coke delivered under this Agreement, that Coke will be free from all liens, encumbrances, and
security interests, that the Coke shall have physical properties that conform to the Product Specifications, and that Seller will perform all of its obligations under the Agreement in all material respects in accordance with all applicable laws and
regulations relating to Seller’s manufacture and delivery of Coke. 
 EXCEPT AS SET FORTH IN THE PRECEDING PARAGRAPH,
SELLER MAKES NO WARRANTY, EITHER EXPRESS OR IMPLIED WITH RESPECT TO ANY PRODUCT, AND SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES, INCLUDING, WITHOUT LIMITATION, WARRANTIES FOR MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS FOR ANY PARTICULAR PURPOSE.
SELLER’S SOLE OBLIGATION AND LIABILITY, AND BUYER’S EXCLUSIVE REMEDY, FOR PRODUCT DEFECTS SHALL BE, AT SELLER’S OPTION, TO REPLACE SUCH DEFECTIVE PRODUCT OR REFUND TO BUYER THE AMOUNT PAID BY BUYER THEREFOR, IN EITHER OF WHICH CASES,
BUYER SHALL, IF REQUESTED BY SELLER AND AT SELLER’S COST, RETURN THE DELIVERED PRODUCT TO SELLER. IN NO EVENT SHALL SELLER’S LIABILITY FOR FAILURE OF COKE TO CONFORM TO THE PRODUCT SPECIFICATIONS EXCEED THE LESSER OF: (A) BUYER’S
PURCHASE PRICE FOR THE COKE THAT IS THE SUBJECT OF THE APPLICABLE CLAIM; OR (B) $* (U.S. DOLLARS *). 
 IN NO EVENT SHALL
SELLER BE LIABLE TO BUYER OR TO ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING WITHOUT LIMITATION LOST PROFITS, LOST SAVINGS, OR LOSS OF BUSINESS OPPORTUNITY) ARISING OUT OF OR RELATING
TO ANY PRODUCT OR SERVICE PROVIDED OR TO BE PROVIDED BY SELLER, OR THE USE OR INABILITY TO USE THE SAME, EVEN IF SELLER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

8.0 Force Majeure. 

8.1 No failure or omission by Seller or Buyer to carry out or observe any of the terms or conditions of this Agreement shall give rise to
any claim against that Party or be deemed a breach of the Agreement if such failure or omission arises from any cause reasonably beyond the control of Seller, including, without limitation: 

 

 6 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 (a) Compliance (voluntary or involuntary) with laws, decrees, guidelines, requests, or
the like of any government or person purporting to act therefore, or of international organizations of which the United States is a member including, without limitation, the International Energy Agency. 

(b) Hostilities or war (declared or undeclared), embargoes, blockades, civil unrest, riots or disorders, terrorism, or sabotage.

 (c) Fires, explosions, lightning, maritime peril, collisions, hurricanes, storms, landslides, earthquakes, floods, and other
acts of nature. 
 (d) Strikes, lockouts, or other labor difficulties (whether or not involving employees of Seller or Buyer).

 (e) Disruption or breakdown of production or transportation facilities, equipment, labor, or materials. 

(f) Closing or restrictions on the use of harbors, railroads, or pipelines. 

(g) Any reduction in availability of crude petroleum or petroleum products and/or other materials necessary to make Coke. 

(h) Any other cause, whether or not of the same class or kind, beyond the control of Seller which prevents or interferes with its
performance of this Agreement. 
 8.2 Upon the occurrence of any of the Force Majeure events described in Section 8.1
hereof, Seller or Buyer shall notify the other promptly in writing of such event and, to the extent possible, inform the other of the expected duration of the Force Majeure event and the quantity of Coke to be affected by the suspension or
curtailment of performance under this Agreement. 
 9.0 Indemnification. 

9.1 Subject to the limitations set forth in Article 7.0, Seller shall defend, indemnify and hold harmless Buyer, its officers, directors,
employees, agents, subsidiaries, affiliates, successors and assigns from and against any and all damages, judgments, liabilities, costs and expenses (including reasonable attorneys’ fees) arising from a claim or lawsuit resulting from
(i) any breach by Seller of its warranties under Section 7.0 hereof and (ii) any contamination, damage or destruction occurring to, or defect existing in, the Coke prior to transfer of title as provided in Section 6.0 hereof.
Buyer shall give Seller prompt written notice of any such claim or lawsuit and shall permit Seller to undertake the defense thereof at Seller’s expense. If Seller accepts the defense, Buyer shall have the right to participate in such defense,
at its own expense, to the extent that in its judgment Buyer may be actually and materially prejudiced by Seller’s defense of the applicable claim or lawsuit. In any claim made or suit brought for which Buyer seeks indemnification under this
Section 7.1, Buyer shall not settle, offer to settle or admit liability or damages without the prior written consent of Seller, such consent not being unreasonably withheld. 

 

 7 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 9.2 Buyer shall defend, indemnify and hold harmless Seller, its officers, directors,
employees, agents, subsidiaries, affiliates, successors and assigns from and against any and all damages, judgments, liabilities, costs and expenses (including reasonable attorneys’ fees) arising from a claim or lawsuit resulting from
(i) the manufacture, sale, distribution, or use of Electrodes by Buyer or any other use of the Coke by Buyer and (ii) contamination, damage or destruction occurring to the Coke after transfer of title as provided in Section 6.0
hereof. Notwithstanding the foregoing, Buyer shall not be required to indemnify and hold harmless Seller for any liability arising, in whole or in part, out of Seller’s breach of warranties under Section 7.0 hereof. Seller shall give Buyer
prompt written notice of any such claim or lawsuit and shall permit Buyer to undertake the defense thereof at Buyer’s expense. Seller shall cooperate in such defense, to the extent requested by Buyer, at Buyer’s expense. If Buyer accepts
the defense, Seller shall have the right to participate in such defense, at its own expense, to the extent that in its judgment Seller may be actually and materially prejudiced by Buyer’s defense of the applicable claim or lawsuit. In any claim
made or suit brought for which Seller seeks indemnification under this Section 7.2, Seller shall not settle, offer to settle or admit liability or damages without the prior written consent of Buyer, such consent not being unreasonably withheld.

 10.0 Termination. 

10.1 Subject to the last sentence of this Section 10.1, this Agreement is subject to termination by either Party for cause, at its
option, if the other Party breaches in any material respect any of its covenants, agreements, obligations, warranties or representations hereunder and such breach remains unremedied for sixty (60) days after delivery of written notice of such
beach by the Party delivering notice of termination; provided that if such breach is a failure by Buyer to make timely payments hereunder, (i) Seller will not be obligated to make any sales following such delinquency, and (ii) if Buyer
remedies such breach, Seller will not be obligated to make sales that were otherwise scheduled during the period following such delinquency and prior to such cure. In addition, Buyer may terminate this Agreement if Seller fails to sell and deliver
the Quarterly Requirement pursuant to Section 3.4(a) for more than two (2) consecutive quarters. 
 10.2 The Agreement
may be terminated at any time by Seller upon written notice if Buyer (i) shall have suffered any materially adverse change in its financial condition, assets, business or property; (ii) becomes insolvent; (iii) fails to pay its debts
or perform its obligations in the ordinary course of business as they mature; (iv) admits in writing its insolvency or inability to pay its debts or perform its obligations as they mature; or (v) becomes subject to any voluntary or
involuntary proceeding in bankruptcy, liquidation, dissolution, receivership, attachment or composition or general assignment for the benefit of creditors; provided that if such condition is assumed involuntarily, it has not been dismissed with
prejudice within sixty (60) days after it begins. 
 10.3 This Agreement may be terminated at any time by Buyer, effective
at the end of any Calendar Year; provided that Buyer must provide written notice to such effect not later than September 30th of such Calendar Year. 
  

 8 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 10.4 In the event this Agreement is terminated pursuant to the last sentence of
Section 10.1 due to a breach by Seller to sell and deliver the Quarterly Requirements, the Parties have agreed that liability for such breach shall not exceed *. 

10.5 Each Party shall use commercially reasonable efforts to mitigate damages resulting from a breach hereof by the other Party.

 11.0 Confidentiality. 

11.1 The Parties hereto acknowledge that Seller has pre-existing and is developing intellectual property and proprietary information
related to coke and coke production, specifically including, but not limited to, the coking process and feedstocks and that Buyer has pre-existing intellectual property and proprietary information related to graphite electrodes, specifically
including, but not limited to, production and performance of graphite electrodes (as to each, the “Confidential Information”). Confidential Information shall not include any information which (i) is or becomes known to the
public through no fault of the Recipient Party, (ii) the Recipient Party can show was received lawfully from any third Party unless the Recipient Party has knowledge that such third Party is subject to restrictions as to the disclosure thereof,
or (iii) the Recipient Party can show is discovered or developed independently by employees of the Recipient Party who did not directly or indirectly use the Confidential Information in such discovery or development. Confidential Information
shall not be deemed to be within the foregoing exceptions merely because any part of said Confidential Information is embodied in general disclosures or because individual features, components or considerations thereof are now or become known to the
public. Notwithstanding anything contained herein, nothing herein shall restrict any activities of GrafTech International Ltd. and its other subsidiaries (collectively, “GrafTech”) so long as Seller shall not have furnished
Buyer’s Confidential Information to GrafTech, and nothing herein shall restrict Seller from using GrafTech’s information or require Seller to use it for the benefit of or share it with Buyer. 

11.2 Each Party shall remain the owner of its Confidential Information. No exchange or disclosure of Confidential Information hereunder
shall be construed to grant either Party any right to or license under the Confidential Information of the other Party. Such disclosure of a Party’s Confidential Information shall be at the absolute discretion of such Party. 

11.3 As used herein the term “Disclosing Party” means the Party disclosing Confidential Information under the terms and
conditions of this Agreement. As used herein the term “Recipient Party” means the Party receiving Confidential Information under the terms and conditions of this Agreement. 

11.4 Confidential Information shall be used by the Recipient Party solely and 

 

 9 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 
exclusively for the purpose of performing and fulfilling the intent of this Agreement and for no other purpose whatsoever. Nothing herein shall be construed as granting to either Party any right
or license under the other Party’s patent or other intellectual property rights, or any right or license to use the other Party’s Confidential Information for any purpose other than as stated above. 

11.5 The Confidential Information disclosed by a Disclosing Party to a Recipient Party shall be deemed the property of such Disclosing
Party. The Confidential Information and all copies thereof shall be returned promptly to the Disclosing Party upon the Disclosing Party’s request (including, without limitation, all documents and all material containing the Disclosing
Party’s Confidential Information) and the Recipient Party shall not retain copies, extracts, summaries, analyses or reproductions, in whole or in part, of the Disclosing Party’s Confidential Information. The Recipient Party will not use
the Confidential Information for its own corporate purposes or otherwise, except in order to satisfy its obligations under this Agreement. 

The Recipient Party agrees that the Confidential Information received from the Disclosing Party will only be divulged to and used by
those employees, consultants and advisors of the Recipient Party, or those of its affiliated companies, who need to know such information in order for the Recipient Party to fulfill its obligations hereunder (the “Permitted
Persons”). The Recipient Party agrees it will not, and will not allow any of the Permitted Persons to, disclose or use any of the Confidential Information, except in accordance with the terms of this Agreement and the Recipient Party shall
be responsible for any and all actions of its Permitted Person if such actions would constitute a breach of this Agreement if the applicable Permitted Person were a party hereto. The Recipient Party shall use the same degree of care in its handling
of the Confidential Information as it uses with regard to its own proprietary information. 
 The Recipient Party agrees that it
will not use for its own benefit, other than in order to satisfy its obligations under this Agreement or disclose Confidential Information of the Disclosing Party to a third Party. If the Recipient Party or any of the Permitted Persons shall attempt
to use or dispose of any of the Confidential Information disclosed by the Disclosing Party, or any duplication or modification thereof, in any manner contrary to the terms of this Agreement, the Disclosing Party shall have the right, in addition to
such other remedies which may be available to it, to injunctive relief enjoining such acts or attempts, it being acknowledged that legal remedies are inadequate. 

11.6 The provisions of this Section 11.0 shall terminate on the date that is ten (10) years after the date of the termination
of this Agreement, unless extended by mutual written consent of the Parties. 
 11.7 Each Party will abide by U.S. Export
Administration Regulations governing the transmittal of unpublished technical data of U.S. origin. Each Party hereby agrees and assures the other Party that neither unpublished technical data of U.S. origin nor the direct products thereof, is
intended to be exported or re-exported directly or 
  

 10 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 
indirectly, to any of the prohibited countries designated by the Office of Export Administration, as amended from time to time, in the absence of a validated export license. 

12.0 Dispute Resolution. 

12.1 The obligations of the Parties pursuant to this Agreement shall be monitored by a management committee (the “Management
Committee”) comprised of two senior manager representatives from each of the Parties who have authority to settle disputes hereunder. The role of the Management Committee shall be to ensure that the Parties are carrying out their
obligations under this Agreement in good faith and to settle disputes arising hereunder. 
 12.2 Any Party may give the other
Party written notice of any dispute not resolved in the ordinary course of business. Within fifteen (15) days after delivery of notice, the Management Committee shall meet at a mutually acceptable time and place and thereafter as often as they
reasonably deem necessary, to attempt to resolve the dispute. If the dispute has not been resolved within sixty (60) days after delivery of notice any Party may initiate subsequent proceedings as contemplated herein. 

12.3 In the event of any disputes involving the Parties, or arising out of or relating to this Agreement, its execution, or performance
hereunder, other than disputes based on third Party pleading following a claim filed against either Party by a third Party (such as for product liability), such disputes (if not resolved by the Management Committee as provided above) shall be
settled by final and binding arbitration before the American Arbitration Association (the “AAA”) or its successor. Either Party may submit the dispute for arbitration by filing a written demand therefore with the AAA and serving the
demand therefore on the other Party. All arbitration hereunder shall be governed by the expedited commercial arbitration rules of the AAA in effect at the time the arbitration is commenced, as the same may be modified during the arbitration. The
arbitrator shall determine whether a dispute is subject to arbitration and resolve matters relating to discovery. The arbitrator may grant injunctive relief, but in no event will an arbitrator be empowered to award punitive or exemplary damages. Any
arbitration pursuant to this Agreement shall be conducted by one arbitrator selected by the Parties, or, if the Parties are unable to agree, by the AAA. The hearings in connection with any arbitration hereunder shall be conducted in New York, at
such time and place selected by the arbitrator. Any decision of the arbitrator shall be in writing and a copy thereof shall be delivered to each of the Parties within thirty (30) days of the conclusion of the hearings. The judgment upon the
award rendered in any such arbitration shall be final and binding upon the Parties and may be entered and enforced in any court having jurisdiction. Each Party shall be responsible for its own legal, consulting and expert costs; provided, however,
that the cost of the Arbitrator and other costs associated with conducting the Arbitration proceedings shall be shared equally between Buyer and Seller. 
  

 11 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 13.0 Miscellaneous. 

13.1 Seller’s Material Safety Data Sheet for the Coke, dated May 3, 2006; attached hereto as Exhibit B is hereby
incorporated by reference into this Agreement. 
 13.2 Nothing contained in this Agreement and no activity by either Party in
the performance of this Agreement shall constitute or be deemed to create between either Party and any of its affiliates an implied right or power or authority of either Party to enter into any agreement or commitment, or to incur any liability or
obligation, on behalf of the other Party it being understood and agreed that each Party shall remain an independent contractor with respect to the other Party. 

13.3 Sections 7.0, 9.0, 11.0, 12.0 and 13.0, and any other provision which, by its very nature, is intended to survive expiration or
termination of this Agreement, shall survive expiration or termination of this Agreement. 
 13.4 All notices and other
communications hereunder shall be given by certified or registered mail, postage prepaid or express delivery courier (provided that any such notice or communication may be transmitted by facsimile machine or e-mail if the original thereof is placed
in the mail on the same day as it is faxed or e-mailed), addressed as follows (or to such other address as either Party shall specify in writing to the other): 
  

			
	If to Seller:	  	 Seadrift Coke L.P.
 PO Box
192 (for US mail service)
 8618 State Hwy 185 North (Fed-Ex/UPS)

Port Lavaca, TX 77979
 Attn:
President

		
	If to Buyer:	  	 C/G Electrodes, LLC
 800
Theresia Street
 Saint Marys, PA 15857

Attn: President

13.5 If any provision of this Agreement is found by a proper authority to be unenforceable or invalid, such unenforceability or
invalidity shall not render this Agreement unenforceable or invalid as a whole and, in such event, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision within the limits
of applicable law or applicable court decisions. 
 13.6 This Agreement may be executed in counterparts in order to provide each
Party with a fully-executed original thereof. This Agreement may not be changed or amended orally, but only by an agreement in writing signed by an authorized representative of each respective Party. This Agreement supersedes all prior agreements
between the Parties for the supply of Coke from and after the date hereof and any such prior agreements are hereby terminated. This Agreement shall not be affected by the 

 

 12 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 
acknowledgement or acceptance by Seller of purchase orders, acknowledgements, sales orders, releases, or by any other forms submitted by Seller or Buyer, which contain other or different terms
and conditions than those included in this Agreement. Each Party acknowledges that it is not relying on any verbal communications not reduced to writing in this Agreement. This Agreement, including the exhibits, reflects the complete understanding
of the Parties with respect to the purchase and supply of Coke from and after the date hereof and constitutes their entire agreement with respect to the purchase and supply of Coke and all prior negotiations, representations, agreements,
understandings, and statements with respect thereto having been merged herein. 
 13.7 No waiver, either express or by course of
dealing or course of performance, of any of the terms and conditions contained in this Agreement, shall be construed as a subsequent waiver of any of the terms and conditions of this Agreement. 

13.8 Neither Party may assign this Agreement without the prior written consent of the other, such consent not to be unreasonably
withheld. Any purported assignment without such consent shall be void. Notwithstanding the foregoing, (a) Seller may assign this Agreement to any member within its consolidated group of affiliated companies without obtaining Buyer’s prior
written consent; provided, that in any event this Agreement shall be binding upon, and enforceable against, any successor-in-interest of Seller, and (b) Buyer may assign this Agreement to a purchaser of Buyer’s St. Mary’s facility,
provided, that this Agreement shall be binding upon, and enforceable against, the applicable successor-in-interest of Buyer and any such successor to Buyer shall remain subject to the terms of Section 3.6 above. 

13.9 This Agreement shall be governed and construed in accordance with the laws of the State of Texas, U.S.A., without reference to its
conflict of law provisions. The United Nations Convention on the International Sale of Goods, 1980, shall not apply to this Agreement. 

(Signature Page Follows) 
  

 13 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives as of the date first written above. 
  

									
	SEADRIFT COKE, L.P.	  		  	C/G ELECTRODES, LLC
					
	By:	  	  
	  		  	By:	  	  

	Name:	  	  
	  		  	Name:	  	  

	Title:	  	  
	  		  	Title:	  	  

  

 14 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 EXHIBIT A 

Product Specifications 
  

			
	 Property
	  	 Specification

		
	 * (*)
	  	* Max.
		
	 * (wt %)
	  	* Max.
		
	 * (*)
	  	* Min.
		
	 * (wt%)
	  	* Max.
		
	 * (wt%)
	  	* Max.
		
	 Sizing Cumulative
	  	
		
	 * (wt%)
	  	* Min.
		
	 * (wt%)
	  	* Max.
		
	 * (wt%)
	  	* Max.

  

 15 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 EXHIBIT B 

MATERIAL SAFETY DATA SHEET – May 3, 2006 

Seadrift Coke 
 8618 Hwy. 185 North 

P.O. Box 192 
 Port Lavaca, Texas 77979

 (361) 552-8373 
 Chemtrec:
(800) 424-9300 
 International: (703) 527-3887 

Product: Calcined Petroleum Needle Coke with *. 

I. IDENTIFICATION: 
  

			
	CHEMICAL FAMILY:	  	Carbon
		
	D.O.T. HAZARD CLASSIFICATION:	  	Inert

 INGREDIENTS (INERT AND
HAZARDOUS): 
  

									
	 Ingredients/Composition
	  	*#	 	%	  	*	 	*
					
	 Petroleum Coke
	  	*	 	*	  	*	 	*
					
	 *
	  	*	 	*	  	*	 	*
					
	 * (* in *)
	  	*	 	*	  	NA*	 	NA*

 +*standard. 

*The *standard is applicable; the *is *. 

II. PHYSICAL DATA: 
  

			
	 MATERIAL IS A SOLID
	  	
		
	 APPEARANCE
	  	*
		
	 *
	  	*
		
	 *
	  	N/A
		
	 *
	  	N/A
		
	 *
	  	N/A
		
	 *
	  	*
		
	 *
	  	N/A
		
	 *
	  	*

  

 16 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

			
	 *
(*)3         
                                   (*)
	  	*
		
	 *,%
	  	*
		
	 ODOR
	  	NONE

 IV. FIRE AND EXPLOSION DATA: 

 

			
	 FLASH POINT:
	  	None
		
	 LOWER/UPPER EXPLOSIVE LIMIT
	  	None
		
	 EXTINGUISHING MEDIA
	  	*
		
	 EXTINGUISHING MEDIA TO AVOID
	  	None
		
	 HAZARDOUS DECOMPOSITION PRODUCTS
	  	*.
		
	 SPECIAL FIREFIGHTING PROCEDURES
	  	*
		
	 UNUSUAL FIRE AND EXPLOSION DATA
	  	* is *.

 V. HEALTH HAZARD DATA: 

 

			
	 PERMISSIBLE EXPOSURE LIMIT (PEL):
	  	See Section II
		
	 PRIMARY ROUTE(S) OF ENTRY:
	  	*
		
	 EFFECTS OF OVEREXPOSURE:
	  	
		
	 EYES:
	  	*
		
	 BREATHING:
	  	*
		
	 SKIN OR SWALLOWING:
	  	No Effect
		
	 FIRST AIDS:
	  	
		
	 SKIN CONTACT:
	  	None necessary
		
	 BREATHING OR SWALLOWING
	  	None necessary
		
	 EYE CONTACT
	  	Flush with water if irritated

  

 17 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

			
	MEDICAL CONDITIONS RECOGNIZED AS POSSIBLY AGGRAVATED BY EXPOSURE	  	*

 VI. REACTIVITY DATA: 

 

			
	*:	  	*
		
	STABILITY	  	Stable
		
	*:	  	*

 VII. SPILL OR LEAK PROCEDURES: 

 

			
	STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED	  	*
		
	WASTE DISPOSAL METHOD	  	*
	
	DISPOSAL MUST BE IN COMPLIANCE WITH FEDERAL, STATE, AND LOCAL LAWS AND REGULATIONS.

VIII. PROTECTIVE EQUIPMENT TO BE USED: 
  

			
	 RESPIRATORY PROTECTION:
	  	*.
		
	 VENTILATION:
	  	*.
		
	 PROTECTIVE GLOVES:
	  	Not required
		
	 EYE PROTECTION:
	  	*.
		
	 OTHER PROTECTIVE EQUIPMENT:
	  	None required.

 IX. SPECIAL PRECAUTIONS OR OTHER
COMMENTS 
 In evaluating *, use *. If * is to be assessed, end analysis * is recommended. 

X. REFERENCES 
  

			
	 ACGIH
	  	Threshold Limit Values for Chemical Substances, current edition
	 OSHA
	  	29 CFR 1910.1000
	 NIOSH
	  	Occupational Health Guidelines

  

 18 

 CONFIDENTIAL TREATMENT HAS BEEN CLAIMED 

FOR PORTIONS OF THIS AGREEMENT IN ACCORDANCE WITH 

RULE 406 UNDER THE SECURITIES ACT OF 1934 AND 

RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 
  

 THIS MATERIAL SAFETY DATA SHEET IS PROVIDED SOLELY FOR YOUR INFORMATION, CONSIDERATION, AND
INVESTIGATION. ANY USE OF THESE DATA AND INFORMATION MUST BE DETERMINED BY THE USER TO BE IN COMPLIANCE WITH APPLICABLE FEDERAL, STATE, AND LOCAL LAW AND REGULATIONS. 

 

 19Separation Agreement - Carol Zilm

 Exhibit 10.32 

 

			
		 	3750 Torrey View Court
		 	San Diego, CA 92130
		 	858.617.2000 tel
		 	 858.617.2900 fax

carefusion.com

 

 

 June 22, 2010 
  

 
  
  

Subject:     Confidential Severance Agreement 

Dear Ms. Zilm: 
 The purpose of this
Confidential Severance Agreement (“Agreement”) is to confirm the understanding and agreement by and between CareFusion Corporation and all of its subsidiaries, affiliates and related companies (collectively referred to as
“CareFusion” or the “Company”), and you (referred to as “You”) concerning your departure from CareFusion. 
  

	1.	Separation Date & Compensation through the Separation Date 

Your at-will employment relationship with the Company will terminate on September 16, 2010 (“Separation Date”). You will
continue as a full-time employee and retain your title through your Separation Date. This notice will be deemed to comply with all applicable WARN act notice provisions. 

Your last day in the office will be July 15, 2010. During the period prior to your Separation Date, you agree to be available to
provide services as requested and cooperate with the Company to ensure a smooth transition with respect to your job responsibilities and any ongoing business matters. 

The Company will continue to pay your regular base salary payments and provide employee benefits from the date of this letter through the
Separation Date. The Company will pay your FY ’10 MIP bonus, using an individual performance factor of not less than 1.0, on the regular schedule for these bonuses, based on actual results and according to the same MIP approval process used for
Company executives (the “FY ’10 MIP Bonus”). 
 On your Separation Date, You will be paid any earned but unused
Paid Time Off (PTO) as of that date, in addition to receiving your final paycheck. 
  

	2.	Group Plan Benefits/Continuation of Health Benefits 

Your medical, dental, vision, life, AD&D and disability insurance will end on your Separation Date. However, You are eligible to
continue medical, dental, and vision health benefits under the Employee Group Benefit Plan (the “Group Plan”) pursuant to applicable federal COBRA guidelines for up to 18 months. If You have questions regarding your COBRA coverage, You may
contact Hewitt directly at (877) 236-5236. 
 Please refer to the 2010 Employee Benefits after Termination of
Employment attachment to this Agreement for more detail. 
  

 1 

	3.	Severance Benefits 

Subject to your execution without modification or revocation of a general release of all claims in the form attached to this Agreement as
Exhibit A (the “Release”) within 60 days following the Separation Date, CareFusion will provide You with the following (collectively, the “Severance Benefits”): 

(i) salary continuation at your current annual base salary of $426,400 for twelve (12) months, effective from your Separation Date,

 (ii) a lump sum cash severance payment equal to the average of your FY ’10 MIP Bonus and your FY ’10 target MIP
bonus, payable within 60 days after your Separation Date, 
 (iii) a lump sum pro-rata portion of your FY ’11 MIP bonus
based on actual Company performance and using an individual performance factor of not less than 1.0 (the “FY ’11 MIP Bonus”), payable at the time FY ’11 MIP bonuses are paid to active employees, 

(iv) should You elect to continue your Group Plan health coverage through COBRA, CareFusion will pay a portion of the cost of COBRA
coverage for twelve (12) months in the same proportion as it shared such costs with You during your employment with CareFusion, less any health assessment or tobacco credit You were receiving as an active employee. Your billing statement will
be adjusted to reflect the cost sharing rate. The portion of the cost of coverage paid by CareFusion will be included as taxable income to You, and 

(v) You will be eligible to receive outplacement services with Lee Hecht Harrison or an outplacement firm mutually agreed upon by You and
CareFusion for the twelve (12) months after the date of this letter. 
 You acknowledge that the Severance Benefits in this
Agreement are over and above any benefits to which You may be entitled and You agree that if you do not execute the Release within 60 days of the Separation Date, or if You revoke or modify Release, You will not be entitled to receive any Severance
Benefits and You will immediately repay to the Company any of the Severance Benefits previously paid or provided to You. 
  

	4.	401(k) Plan 

 You are
fully vested in any money you have personally contributed to your plan account and in any Company matching contributions. In order to be vested in all Employer contributions in your 401(k) plan account, You must have a minimum of three
(3) years of service. 
 If You have any questions regarding your 401(k) account, please contact the CareFusion Financial
Plans Service Center at (800) 835-5095. 
  

	5.	Equity Awards 

 Following
the Separation Date and CareFusion’s timely receipt of the Release without revocation or modification, CareFusion will provide You with 24 months to exercise your CareFusion and Cardinal Health vested equity. All other terms and conditions in
each grant award, including the non-compete, non-solicitation and other covenants, will remain in full force and effect. 
  

 2 

 You can exercise Cardinal Health options, if applicable, by visiting
www.ubs.com/onesource/cah, or You can call UBS at (866) 514-4318. You can exercise CareFusion options, if applicable by visiting www.ubs.com/onesource/cfn, or You can call UBS at (877) 236-5208. Also, unless otherwise provided for
in Your award agreement, any unvested stock options or restricted stock, if any, will be cancelled on the Separation Date. 
  

	6.	Transition Procedure 

 The
Company’s agreement to provide the Severance Benefits is further contingent on and subject to your agreement to: (a) continue to conduct your activities in a professional manner and to cooperate with CareFusion, its subsidiaries,
affiliates and related companies in all reasonable ways to achieve a smooth transition and resolution to any open items on which You were working; (b) not intentionally injure CareFusion and any of its subsidiaries, affiliates or related
companies in any way, including with respect to company property, customers, or personnel; (c) return any Company property in your possession including, but not limited to, proprietary and confidential information, laptop computers,
blackberries or other pda devices, cell phones, memory cards, all credit cards, office or warehouse keys, supplies or equipment, all company documents, computer files and all copies thereof; (d) refrain from any conduct, activity, or
conversation which is intended to or does interfere with or disparage the relationships between CareFusion and its subsidiaries, affiliates and related companies and their respective officers, directors, employees, customers, suppliers or others,
both prior to and following the Separation Date; and (e) refrain from disparaging or defaming the goodwill or reputation of CareFusion and its employees, agents, officers, and directors. 

 

	7.	Payment for American Express Charges 

You agree and understand that You are responsible for the payment of all outstanding balances and charges incurred by You on the American
Express Corporate Card. You represent that You will fully disclose all charges made to such account and You hereby agree and authorize the Company to pay all current charges, plus any additional charges that may be posted to this account, and to
deduct such payment from any and all payments that You may be due from the Company including, but not limited to, any expense reimbursements You may have requested, any bonus check or other payment by the Company to You, and any severance payment or
salary continuation payable to You (with any deduction from any amounts that are considered deferred compensation subject to Section 409A being limited to $5,000). 

In the event that the amount due to American Express exceeds the amount payable by the Company to You or which may be withheld or deducted
by the Company, You agree to forward such additional payment to American Express within twenty (20) days of the final billing statement. You further agree to hold the Company harmless for any amounts paid by the Company to American Express and
to reimburse the Company for any payment to American Express that exceeds any amount or payment that may be payable to You by the Company or that may be withheld or deducted by the Company. You further agree to submit all outstanding expense reports
with appropriate supporting receipts for reimbursement to my attention within twenty (20) days of your Separation Date. 
  

 3 

	8.	Proprietary Information and Confidentiality 

You agree not to take, use, disclose, alter, or copy proprietary or confidential information pertaining to CareFusion, its subsidiaries,
affiliates or related companies. In addition, You agree that the terms and conditions of this Agreement, and any attachments, amendments or addendums to this Agreement, if any, shall remain confidential, and You shall not disclose, directly or
indirectly, the existence or terms of this Agreement and any attachments, amendments or addendums to any other person or entity, except only: (A) as You may be specifically permitted or directed by CareFusion in writing to do so; (B) to
your personal legal, accounting and financial advisors, and your immediate family; or (C) as may be required by law. You hereby understand and agree that this covenant is a material element of this Agreement. 

 

	9.	No Solicitations 

 You
agree that for 12 months after your Separation Date, You will not, without CareFusion’s prior written consent, directly or indirectly: solicit, recruit, induce or otherwise encourage CareFusion employees, contractors or anyone else providing
services to CareFusion to end their employment or business relationship with CareFusion or to engage in any competitive business. 
  

	10.	Cooperation 

 In
consideration for the Severance Benefits and other benefits You are receiving, You agree to fully cooperate with and assist CareFusion, its subsidiaries, affiliates and related companies and their respective representatives and attorneys as
requested with respect to any matters, claims, actions, disputes, litigation or arbitrations, internal or government investigations or other dispute resolutions by being available to provide affidavits, interviews, depositions and/or testimony in
regard to any matters in which You are or have been involved or with respect to which You have relevant information. CareFusion will reimburse You for reasonable expenses You may incur in connection with providing such cooperation. Any such
reimbursement will be made no later than the end of the calendar year after the calendar year in which the expense was incurred, provided documentation of the expense is provided by You to CareFusion within ten business days before that date. You
further agree that should You be contacted (directly or indirectly) by any person or entity regarding any matters pertaining to your former employment to CareFusion, You shall promptly notify the CareFusion Legal Department in writing, addressed to
3750 Torrey View Court, San Diego, CA 92130. 
 Nothing in this Agreement is intended to: (a) limit your ability to respond
truthfully to inquiries from, or otherwise cooperate with, any governmental or regulatory investigation concerning facts or events that arose during the period of your employment with CareFusion; or (b) create any obligation on your part to
inform the Company about the fact or substance of any communications You may have with any governmental authorities in connection with any pending and/or future actions. 

 

	11.	Non-Disparagement 

 You
agree not to disparage, defame or otherwise detrimentally comment upon CareFusion, including its business practices, products, or services. You acknowledge that such comment shall cause serious damage to CareFusion. 

 

	12.	Non-Disclosure and Other Agreements 

You agree that this Agreement will not supercede any existing Non-Disclosure Agreement(s) or any other agreements or restrictive covenants
executed by You or to which You are subject relating to non-solicitation, non-competition, confidentiality and/or CareFusion’s proprietary information or intellectual property. 

 

 4 

	13.	Review of Agreement 

 You
agree and represent that You have been advised of and fully understand your right to discuss all aspects of this Agreement with counsel of your choice. Your execution of this Agreement establishes that, if You wish the advice of counsel, You have
done so by the date You signed the Agreement. 
  

	14.	Tax Matters 

 CareFusion
makes no representation as to the Federal, State or Local tax treatment of any payments promised herein. You are solely responsible for any income taxes, excise taxes or other taxes arising from any payments made to You or others on your behalf
(including offsets) and CareFusion will not reimburse You for such taxes nor “gross up” any payments so as to produce any particular result for you net of taxes. CareFusion may withhold amounts for Federal, State and Local taxes as
required by applicable law. CareFusion will report all payments hereunder to the proper tax authorities in accordance with its determination as to its reporting obligation, and no such determination made in good faith shall give rise to any
liability to You. In signing this Agreement You affirm that You have not relied on any representations made by CareFusion with respect to the taxation of any payments. For purposes of Section 409A, each installment payment under the Agreement
shall be treated as a separate payment. “Separation Date” or words of similar import as used in this Agreement mean, for purposes of any payments to be made under this Agreement that are payments of “deferred compensation”
subject to Section 409A, your “separation from service” which for purposes of this Agreement shall mean a reasonably anticipated reduction of the level of bona fide services to a level that is less than 50% of the average level of
services You provided in the immediately preceding 36 months. To the extent that any portion of the Severance Benefits constitutes deferred compensation subject to Section 409A, some portion of the amount payable may have to be delayed and paid
on the first business day that is at least six months after your Separation Date. The Company will separately notify you if this restriction is applicable to your Severance Benefits. 

 

	15.	Full Compliance 

 You
acknowledge and agree that CareFusion’s agreement to provide Severance Benefits under this Agreement is expressly contingent upon your full compliance with the provisions of this Agreement and any other Agreements, if any, between You and
CareFusion. 
  

	16.	Successors 

 You and
anyone who succeeds to your rights and responsibilities are bound by this Agreement and this Agreement will accrue to the benefit of and may be enforced by CareFusion, its subsidiaries, affiliates and related companies and their successors and
assigns. 
  

	17.	Severability 

 You agree
that the validity or unenforceability of any provision of this Agreement shall not affect the validity or unenforceability of any remaining provisions. 
  

	18.	No Representations/Entire Agreement 

You acknowledge that You do not, and have not, relied upon any representation or statement not set forth herein made by CareFusion or any
representative or agent thereof. The parties acknowledge that this agreement contains the entire understanding of the parties with respect to the matters set forth herein. 
  

 5 

	19.	Amendment; No Admission; Governing Law 

This Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the parties to this
Agreement. It is not, and shall not, be interpreted or construed as an admission or indication that the Company has engaged in any wrongful or unlawful conduct of any kind. 

You agree that all questions concerning the intention, validity or meaning of this Agreement shall be construed and resolved according to
the laws of the State of California. You also designate the federal and state courts of San Diego, California as the courts of competent jurisdiction and venue for any actions or proceedings related to this Agreement, and hereby irrevocably consent
to such designation, jurisdiction and venue. 
 I believe the foregoing accurately reflects the terms of your separation from CareFusion, and
ask that You sign an extra copy of this letter and return it to me to confirm your agreement. 
  

	
	Sincerely,
	
	CAREFUSION
	
	 /s/ Cathy Cooney

	Cathy Cooney,
	Executive Vice-President, Human Resources

 Agreed to:

  

					
	/s/ Carol Zilm	  	6-28-10	  	
	Carol Zilm	  	Date	  	

  

 6 

 EXHIBIT A 

General Release 

I, Carol Zilm, in consideration of the Severance Benefits (the “Severance Benefits”) described in the Confidential Severance
Agreement dated June 22, 2010 (the “Severance Agreement”), do hereby release CareFusion Corporation and all of its subsidiaries, affiliates and related companies (collectively referred to as “CareFusion” or the
“Company”) by execution of this release (the “Release”) from any and all claims and causes of action that may exist, whether known or unknown, as of the date of my execution of this Release with the exception of any unemployment
compensation claim I may have and any other claims that cannot be waived by law. I agree that this Release applies to all officers, directors, employees and other representatives of CareFusion, its subsidiaries, affiliates and related companies
(collectively “the Releasees”). This Release relates to all causes of action to the extent permitted by law, including, but not limited to, claims under CareFusion’s policies or practices, federal and state fair employment practices
or discrimination laws, laws pertaining to breach of employment contract or wrongful termination, claims under any applicable state or federal employment, labor or wage and hour statute, and claims under the Age Discrimination and Employment Act
(ADEA), the Worker Adjustment and Retraining Notification Act (WARN) and any applicable state laws of similar intent. 
 In
addition, I agree that I will not initiate, bring, or prosecute any suit, action or grievance against any of the Releasees for any released claim in any federal, state, county or municipal court, or any arbitral forum, except as specifically stated
below. I further agree that if I do so, I shall be liable for the payment of all damages and costs, including attorneys’ fees, incurred by any of the Releasees in connection with my suit, action, or grievance. I also waive my right to any
relief sought in connection with such claims, including any right to damages, attorneys’ fees, costs, and all other legal or equitable relief.

This agreement not to sue does not prohibit me from pursuing a lawsuit, claim, or charge to challenge the validity or enforceability of
this agreement under the Age Discrimination in Employment Act (“ADEA”) or the Older Workers Benefit Protection Act (“OWBPA”), nor does it render me liable for damages or costs, including attorneys’ fees, incurred by the
Releasees in connection with a lawsuit, claim, or charge to challenge the validity or enforceability of this agreement under the ADEA or the OWBPA. This agreement not to sue also does not prohibit me from filing charges with government agencies
or participating in any investigation resulting from such charges. However, under this agreement, I agree not to accept any monetary or personal relief or remedy, including but not limited to back pay, front pay, or reinstatement, that may be
awarded in connection with such charges. In addition, this general Release is not intended to bar any claims for workers’ compensation benefits. 

This Release does not apply to any claims arising after my execution of this general Release. 

 

 7 

 Complete Release 

I also expressly agree that you have read, understand, and intend to waive any and all rights or benefits described in Section 1542
of the California Civil Code, which provides as follows: 
 ‘A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.’ 

Thus, notwithstanding the provisions of Section 1542, and for the express purpose of implementing a full and complete release and
discharge of Releasees, I expressly acknowledge that this Release is intended to include within its effect, without limitation, all claims I do not know or suspect to exist in my favor at the time of execution of this Release, and this Release
contemplates the extinguishment of any such claim(s). 
 Written Affirmation of No Present Violation 

I certify and warrant that: (a) I am not presently aware of any unreported violation of CareFusion’s Code of Conduct; (b) I
am not presently aware of any work-related injury not properly disclosed to CareFusion; (c) upon receiving the payments outlined in the Severance Agreement, I will have received all medical and other leave time and pay to which I are entitled;
(d) I will have been paid for all hours worked; and (e) I have not exercised any actual or apparent authority by or on behalf of CareFusion that I have not specifically disclosed to CareFusion. 

Full Compliance 
 I
acknowledge and agree that CareFusion’s agreement to provide Severance Benefits under this Release is expressly contingent upon my full compliance with the provisions of this Release, the Severance Agreement and any other agreements, if any,
between myself and CareFusion. 
 Successors 

I and anyone who succeeds to my rights and responsibilities are bound by this Release and this Release will accrue to the benefit of and
may be enforced by CareFusion, its subsidiaries, affiliates and related companies and their successors and assigns. 
 Severability

 I agree that the validity or unenforceability of any provision of this Release shall not affect the validity or
unenforceability of any remaining provisions. 
 No Representations/Entire Agreement 

I acknowledge that I do not, and have not, relied upon any representation or statement not set forth herein made by any of the Releasees,
their agents or representatives. The parties acknowledge that this Release and the Severance Agreement contain the entire understanding of the parties with respect to the matters set forth herein. 

Amendment; No Admission; Governing Law 

This Release may be amended or waived if, and only if, such amendment or waiver is in writing and signed by the Company and by me. It is
not, and shall not, be interpreted or construed as an admission or indication that the Company has engaged in any wrongful or unlawful conduct of any kind. 

I agree that all questions concerning the intention, validity or meaning of this Release shall be construed and resolved according to the
laws of the State of California. I also designate the federal and state courts of San Diego, California as the courts of competent jurisdiction and venue for any actions or proceedings related to this Release, and hereby irrevocably consent to such
designation, jurisdiction and venue. 
  

 8 

 Review of Release 

I agree and represent that I have been advised of and fully understand my right to discuss all aspects of this Release with counsel of my
choice. My execution of this Release establishes that, if I wish the advice of counsel, I have done so by the date I signed this Release, and that I was given at least 45 days to consider whether or not to sign. I may sign this Release before the
end of the 45 day period and I agree that if I decide to shorten this time period for signing, my decision was knowing and voluntary. I agree that a change to the Severance Agreement, whether material or immaterial, does not restart the running of
said period. 
 I will have 7 days from the date that I sign this Release to revoke the Release and to change my mind, in which
case this Release shall be ineffective and of no legal force. If I so revoke this Release, there will be no obligation on the part of CareFusion to provide me with any of the Severance Benefits described in the Severance Agreement and I agree to
repay to CareFusion any such Severance Benefits previously paid or provided to me. 
  

					
	/s/ Carol Zilm	  	6-28-10	  	
	Carol Zilm	  	Date	  	

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]